Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Background Vaccine effectiveness studies have not differentiated the effect of the delta (B.
1.617. 2) variant and potential waning immunity in observed reductions in effectiveness …
1.617. 2) variant and potential waning immunity in observed reductions in effectiveness …
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar
Abstract SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants are genetically divergent. We
conducted a matched, test-negative, case-control study to estimate duration of protection of …
conducted a matched, test-negative, case-control study to estimate duration of protection of …
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
LJ Abu-Raddad, H Chemaitelly… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
Effects of previous infection and vaccination on symptomatic omicron infections
Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with …
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with …
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet Infectious Diseases, 2022 - thelancet.com
Background Real-world evidence supporting vaccination against COVID-19 in individuals
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …
who have recovered from a previous SARS-CoV-2 infection is sparse. We aimed to …